Somatic hypermutation shapes the viral escape profile of SARS-CoV-2 neutralising antibodies.

ABSTRACT:

Background

Since the onset of the COVID-19 pandemic, SARS-CoV-2 neutralising monoclonal antibodies (mAbs) are being developed for clinical use. With the appearance of new virus variants, most mAbs lost their virus-neutralising activity, highlighting the complexity of mAb development under conditions of continuous SARS-CoV-2 evolution.

Methods

Hamsters were treated with SARS-CoV-2 neutralising mAbs and then challenged with SARS-CoV-2. Recombinant VSV expressing the spike protein of SARS-CoV-2 was utilised in an in vitro system to select for antibody escape variants. Surface plasmon resonance measurements were performed to characterise the binding affinity and epitope of various mAbs. Fc-mediated effector functions of neutralising and non-neutralising mAb combinations were det

SUBMITTER: Bruhn M 

PROVIDER: S-EPMC12148588 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature